Cargando…
US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer
Autores principales: | Shord, Stacy S., Zhu, Hao, Liu, Jiang, Rahman, Atiqur, Booth, Brian, Zineh, Issam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681452/ https://www.ncbi.nlm.nih.gov/pubmed/37641498 http://dx.doi.org/10.1002/psp4.13033 |
Ejemplares similares
-
Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development
por: Subramaniam, Sriram, et al.
Publicado: (2023) -
The clinical pharmacogeneticist: An emerging regulatory scientist at the US Food and Drug Administration
por: Zineh, Issam, et al.
Publicado: (2010) -
Quantitative Systems Pharmacology: A Regulatory Perspective on Translation
por: Zineh, Issam
Publicado: (2019) -
A Holistic and Integrative Approach for Advancing Model‐Informed Drug Development
por: Madabushi, Rajanikanth, et al.
Publicado: (2019) -
Editorial: Embracing Scrutiny
por: Goehl, Thomas J.
Publicado: (2004)